| Catalog No. | Size | Price (USD) |
| 50959-T16-50 | 50 µL | $147.96 |
| 50959-T16-100 | 100 µL | $251.64 |
| 50959-T16-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-CNDP1 Antibody, Rabbit Polyclonal |
| Validated applications | ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Mouse |
| Specificity | Mouse CNDP1 |
| Immunogen | Recombinant Mouse CNDP1 protein (Catalog#50959-M08H) |
| Preparation | Produced in rabbits immunized with purified, recombinant Mouse CNDP1 (Catalog#50959-M08H; Q8BUG2; Met1-Tyr492). CNDP1 specific IgG was purified by Mouse CNDP1 affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A & Antigen Affinity |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-Cn1 Antibody; Anti-Cndp1 Antibody
Background Information
| Full Name | carnosine dipeptidase 1 (metallopeptidase M20 family) |
| Description | CNDP1, also known as carnosine dipeptidase 1, glutamate carboxypeptidase-like protein 2 (CPGL-2) or carnosinase 1 (CN1), is a member of the M20 metalloprotease family. The CNDP1 gene contains trinucleotide (CTG) repeat length polymorphism in the coding region, which has been demonstrated to be associated with susceptibility to developing diabetic nephropathy, for carnosine protection against the adverse effects of high glucose levels on renal cells. In humans, CNDP1 is secreted from the liver into the serum. In other mammals, including rodents, CNDP1 is expressed exclusively within the kidney and lacks a signal peptide. CNDP1 protein is a secreted homodimeric dipeptidase that specifically hydrolyzes L-carnosine (β-alanyl-L-histidine), and is identified as human carnosinase expressed in the brain. CNDP1 has been associated with diabetic nephropathy in Europeans and European Americans, but not African-Americans. It was identified and confirmed as a risk factor, were cross-sectional and mostly in patients with type 2 diabetes. The polymorphisms of CNDP1 can be excluded as a risk factor for nephropathy in type 1 diabetes. In addition, CNDP1 is also suggested to be implicated in the actions of neuroprotection and neurotransmiting. |
| References |
|
